Zentalis Pharmaceuticals Inc Ownership
$2.24
3.45%
Nasdaq, Oct 15, 04:35 pm EDT.
Closed.
Zentalis Pharmaceuticals Inc Top Shareholders
| # | Holder | Shares | % of Shares Out | Change | Filing Date |
|---|---|---|---|---|---|
| 1 |
Walters Group
|
17.845m | 24.90% | +4.335m | Aug 14 2026 |
| 2 |
5AM Ventures
|
3.948m | 5.51% | — | Jun 30 2026 |
| 3 |
Squadron Capital Management LLC
|
3.700m | 5.16% | +69.000k | Jun 30 2026 |
| 4 |
BlackRock Institutional Trust Company, N.A.
|
3.459m | 4.83% | +2.295m | Jun 30 2026 |
| 5 |
Two Sigma Investments, LP
|
3.025m | 4.22% | +68.410k | Jun 30 2026 |
|
1
Walters Group
|
24.90%
17.845m
|
|
2
5AM Ventures
|
5.51%
3.948m
|
|
3
Squadron Capital Management LLC
|
5.16%
3.700m
|
|
4
BlackRock Institutional Trust Company, N.A.
|
4.83%
3.459m
|
|
5
Two Sigma Investments, LP
|
4.22%
3.025m
|
| The largest shareholders show who really holds influence: big institutional owners shape a stock's liquidity, and building or cutting positions can move the price. | |
| The 5 largest shareholders together hold 44.62% of Zentalis Pharmaceuticals Inc, with Walters Group the biggest at 24.90%, followed by 5AM Ventures (5.51%) and Squadron Capital Management LLC (5.16%). |
Recent Zentalis Pharmaceuticals Inc Insider Transactions
Powered by
| Date | Insider & Role | Type | Price | Quantity | Volume |
|---|---|---|---|---|---|
| Oct 15 2026 |
John Mitchell
CEO
|
Purchases
|
$182.45 | + 15,000 | $2,736,750 |
| Oct 12 2026 |
Sarah Chen
CFO
|
Sales
|
$179.80 | - 8,500 | $1,528,300 |
| Oct 08 2026 |
Robert Williams
COO
|
Purchases
|
$175.20 | + 12,000 | $2,102,400 |
| Oct 03 2026 |
Emily Rodriguez
Director
|
Sales
|
$181.30 | - 5,200 | $942,760 |
| Sep 27 2026 |
Michael Thompson
SVP Operations
|
Purchases
|
$170.50 | + 20,000 | $3,410,000 |
| Sep 20 2026 |
Lisa Park
General Counsel
|
Sales
|
$177.90 | - 6,800 | $1,209,720 |
| No transactions found for this filter. | |||||
|
John Mitchell
PURCHASES
|
Oct 15 2026
$182.45
|
|
Sarah Chen
SALES
|
Oct 12 2026
$179.80
|
|
Robert Williams
PURCHASES
|
Oct 08 2026
$175.20
|
|
Emily Rodriguez
SALES
|
Oct 03 2026
$181.30
|
|
Michael Thompson
PURCHASES
|
Sep 27 2026
$170.50
|
|
Lisa Park
SALES
|
Sep 20 2026
$177.90
|
| No transactions found for this filter. | |
| Insider transactions show you what executives, directors and major shareholders do with their own stock: people who know the company from the inside. Buys are the most telling signal, because insiders invest their own money. Sells are harder to read, since they can also be driven by taxes, diversification or expiring option programs. |
Zentalis Pharmaceuticals Inc Short interest
Powered by
| Short interest shows what share of a stock's freely tradable shares (float) is currently sold short, meaning held by investors betting on falling prices. A high or rising level can be read two ways: it reflects the skepticism of many market participants, but also carries upside potential. Because if the stock rises, short sellers have to buy back, which can push the price up even further. This effect is called a short squeeze. | |
| The short interest in Zentalis Pharmaceuticals Inc has held steady at around 7.1% of the float over the past 12 months. Short sellers' positioning has barely changed in this period. |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
